Figure 1. Pkd1 mutant renal epithelial cells and tissues demonstrated increased expression of SMYD2.

(A) Western blot analysis of SMYD2 expression from whole cell lysates in Pkd1 WT, Pkd1^null/null MEK cells (Null), Pkd1-heterozygous PH2 cells, and Pkd1-homozygous PN24 cells (top panel). Relative SMYD2 expression was quantified from 3 independent immunoblots and standardized to actin (bottom panel). (B) qRT-PCR analysis of relative Smyd2 mRNA expression in WT, Null, PH2, and PN24 cells. (C) Western blot analysis of SMYD2 expression in P7 kidneys from Pkd1^+/+:Ksp-Cre (WT) and Pkd1^fl/fl:Ksp-Cre (Homo) neonates (top panel). Relative SMYD2 expression in the kidneys (bottom panel) as standardized to actin. (D) qRT-PCR analysis of relative Smyd2 mRNA expression in the kidneys described in C. n = 3. (E) Western blot analysis of SMYD2 expression in primary human ADPKD and NHK cells. Data are representative of 2 independent experiments. (F) Immunohistochemistry analysis indicated that SMYD2 expression was increased in cyst-lining epithelia in human ADPKD kidneys (bottom panel) but not in normal human kidneys (top panel). Scale bars: 50 μm. (G) Western blot analysis of SMYD2 expression in mIMCD3 cells with or without knockdown of Pkd1 with shRNA and/or Smyd2 with siRNA. Representative data from 3 independent experiments are shown.